Abstract: This inventions relates to a method of treating malignant tumors of the pancreatic, colic or gastric origin whose growth is increase by bioactive polypeptides comprising administering an anti-tumor effective amount of proglumide or pharmaceutical acceptables salt thereof to a patient afflicted with said malignant tumors.

Abstract: New original derivatives are described of 5-pentylamino-5-oxopentanoic and 4-pentylamino-4-oxobutanoic acids having the formula: ##STR1## in which n is 1 or 2, R.sub.1 is selected from the groups 2-naphthyl, 2 (or 3)-quinolinyl, 2 (or 3)-indolyl, 2 (or 3)-benzofuranyl, 2 (or 3)-benzothiophenyl, and R.sub.2 is a pentyl group or an alkoxyalkyl group with 4 or 5 carbon atoms, preferably pentyl, 2-ethoxyethyl, 3-methoxypropyl or 3-ethoxypropyl.The compounds have a powerful antagonistic activity towards cholecystokinin and are particularly useful in the treatment of illnesses of the digestive system, such as colitis, biliary diskinesia, pancreatitis or in the treatment of disorders of the central nervous system imputable to deficiencies in the physiological neuron levels of cholecystokinin or other related bioactive polypeptides.

Abstract: N-acylated derivatives of L-tryptophan of general formula (I), ##STR1## in which R is selected from the group consisting of: (a) a phenyl group, mono-substituted or di-substituted in the meta and para positions with halogens, linear or branched alkyl groups containing from 1 to 9 carbon atoms, the cyano group or the trifluoromethyl group, (b) a benzyloxy group, mono-substituted or di-substituted in the meta and para position with substituents selected from those indicated at (a), and (c) a benzydryloxy group. The derivatives are used in therapy, particularly for human pain relief, in the treatment of pathological conditions of the central nervous system and of pathological intestinal conditions.

Abstract: New original derivatives are described of 5-pentylamino-5-oxopentanoic and 4-pentylamino-4-oxobutasnoic acids having the formula: ##STR1## in which n is 1 or 2, R.sub.1 is selected from the groups 2-naphthyl, 2 (or 3)-quinolinyl, 2 (or 3)-indolyl, 2 (or 3)-benzofuranyl, 2 (or 3)-benzothiophenyl, and R.sub.2 is a pentyl group or an alkoxyalkyl group with 4 or 5 carbon atoms, preferably pentyl, 2-ethoxyethyl, 3-methoxypropyl or 3-ethoxypropyl.The compounds have a powerful antagonistic activity towards cholecystokinin and are particularly useful in the treatment of illnesses of the digestive system, such as colitis, biliary diskinesia, pancreatitis or in the treatment of disorders of the central nervous system imputable to deficiencies in the physiological neuron levels of cholecystokinin or other related bioactive polypeptides.

Abstract: New derivatives of D,L-glutamic acid and D,L-aspartic acid are described having the formulae: ##STR1## in which n is equal to 1 or 2, R.sub.1 is a phenyl group mono-, di- or tri-substituted with linear or branched C.sub.1 -C.sub.4 alkyl groups, which may be the same or different, or with halogens, with a cyano group or a trifluoromethyl group, and in which R.sub.2 is selected from the group consisting of morpholino, piperidino and amino with one or two linear, branched or cyclic alkyl group substituents containing from 1 to 8 carbon atoms, which may be the same or different, or a pharmaceutically-acceptable salt thereof.The compounds have an antagonistic activity towards bioactive polypeptides and are useful particularly in the treatment of illnesses of the digestive system and the central nervous system, as pain killers, and for the treatment of anorexia and all those affections (for example tumours) in which exogenous or endogenous bioactive polypeptides are involved.

Abstract: The compound consists of a mixed salt of glucosamine sulphate and sodium chloride corresponding to the formula: ##STR1## and is in the form of a crystalline powder with a melting point above 300.degree. C. The salt is stable at ambient temperatures and humidities and has pharmacological properties practically identical to those of glucosamine sulphate.

Abstract: The subject of the invention is a new use of D,L-4-benzamido-N,N-dipropyl-glutaramic acid (proglumide) in human pain relief. According to the invention proglumide is used both alone, at dosages of from 0.5 to 30 mg/kg of body weight, and in association with analgesic-narcotic drugs, it being able to potentiate the analgesic activity of these drugs.

Abstract: Compounds having the general formula: ##STR1## in which: Ad is 1-adamantyl (C.sub.10 H.sub.15) radicalA is oxygen atom or --NH--(imino) groupR is --CH.sub.3 (methyl) group or --C.sub.2 H.sub.5 (ethyl) groupR' is a linear aliphatic chain containing from 10 to 12 atoms of carbonX.sup.- is a halide ion.The halide may be chlorine or bromine. The compounds exhibit an antibacterial, antimould and antiprotozoic activity and may be formulated as pharmaceutical and cosmetic preparations or used as preservatives for food products.

Abstract: 5-nitro-imidazole derivatives of the formula ##STR1## in which R.sub.1 is hydrogen, methyl, ethyl or phenyl, n is 2 or 3, and R.sub.2 is methyl, ethyl, carboxymethyl or carboxyethyl, and the pharamceutically acceptable acid addition salts thereof, useful as antiprotozoics.

Abstract: Tyrosine derivatives of the formula: ##STR1## wherein: R.sub.1 is a linear or branched-chain alkyl group having 1-6 carbon atoms, terminating by a tertiary amino group; R.sub. 2 is an unsubstituted, monosubstituted or di-substituted phenyl or benzyloxy group, the substituent being --Cl, --Br, --NO.sub.2, --OCH.sub.3, --CH.sub.3 or --CF.sub.3 ; R.sub.3 is a primary, secondary or tertiary amino group or an aryl-alkylamino group having 7-9 carbon atoms; and salts of said tyrosine derivatives with pharmaceutically acceptable acids.

Abstract: Pharmaceutically active L-tryptophane compounds comprising the compound of the formula: ##STR1## AND ITS CALCIUM, MAGNESIUM AND ALUMINUM SALTS. These compounds exhibit superior pharmacologic activity on the gastroenteric tract.

Abstract: Anti-inflammatory antirheumatic compounds of the formula: ##SPC1##Wherein n.sub.1 and n.sub.2 are each either 2 or 3, and wherein the two tertiary amino-groups may, if desired, be present in the form salified by a pharmaceutically acceptable acid such as oxalic, citric, maleic, fumaric or hydrochloric acid. The preferred compound is N'-2-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetoxy]-ethyl-N-3-(N -benzoyl-N',N'-di-n-propyl-DL-isoglutaminoyl)-oxypropyl-piperazine, preferably in the form of dimaleate.